Published in Redox Biol on June 18, 2015
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem (1969) 15.62
Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem (1980) 10.52
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A (2010) 8.12
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12
Antioxidants accelerate lung cancer progression in mice. Sci Transl Med (2014) 2.23
Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem (2003) 2.14
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell (2012) 2.08
2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res (2007) 2.03
Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med (2006) 1.69
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A (2011) 1.68
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer (2006) 1.34
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev (2011) 1.30
Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res (2004) 1.28
The in vivo distribution of oxidized and reduced thioredoxin in Escherichia coli. J Biol Chem (1982) 1.20
Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS Chem Biol (2013) 1.12
Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med (2011) 1.12
Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res (2011) 1.10
TGF-beta-activated kinase 1 signaling maintains intestinal integrity by preventing accumulation of reactive oxygen species in the intestinal epithelium. J Immunol (2010) 1.07
Pharmacology of auranofin: overview and update. Scand J Rheumatol Suppl (1986) 0.99
Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J Oncol (2009) 0.98
Epithelial transforming growth factor β-activated kinase 1 (TAK1) is activated through two independent mechanisms and regulates reactive oxygen species. Proc Natl Acad Sci U S A (2012) 0.95
TAK1 kinase signaling regulates embryonic angiogenesis by modulating endothelial cell survival and migration. Blood (2012) 0.93
Effects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells. Anticancer Res (2012) 0.93
Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. Redox Biol (2014) 0.88